ImmunityBio, NantKwest launch COVID-19 vaccine trial

By The Science Advisory Board staff writers

October 22, 2020 -- ImmunityBio and NantKwest have launched phase I of a clinical trial for a COVID-19 vaccine candidate.

The first patient has received the second generation hAd5 COVID-19 vaccine, which targets both the outer spike protein and inner nucleocapsid of the SARS-CoV-2 virus. The two firms hope the vaccine will lead to long-term T cell and antibody immunity to the SARS-CoV-2 virus, the companies said.

hAd5 COVID-19 vaccine
First patient receives California-based ImmunityBio's second-generation hAd5 COVID-19 vaccine, which targets both the outer spike protein and inner nucleocapsid, leading to potential long-term T cell and antibody immunity to the SARS-CoV-2 virus. Image courtesy of NantKWest.

The trial is being conducted at the Hoag Center for Research and Education in Newport Beach, CA, and is enrolling 35 healthy participants between the ages of 18 and 55.

ImmunityBio begins phase I trial for its COVID-19 vaccine candidate
ImmunityBio has been authorized by the U.S. Food and Drug Administration to begin a phase I clinical trial of its hAd5-COVID-19 vaccine candidate.
NantKwest scales up COVID-19 stem cell therapy
NantKwest announced that it received investigational new drug authorization from the U.S. Food and Drug Administration (FDA) to treat patients with acute...

Copyright © 2020 scienceboard.net


Conferences
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter